Type of Mesothelioma:
Effectiveness of Surgical Treatment on Survival of Patients with Malignant Pleural Mesothelioma
Cancers 2025 July 16 [Link] Renata Báez-Saldaña, María Esther Marmolejo-Torres, Marco Antonio Iñiguez-García, Aída Jiménez-Corona, Juan Alberto Berrios-Mejía Abstract Background: The benefit of surgery for malignant pleural mesothelioma is highly debated, as few robust clinical trials show its effectiveness. Objective: To examine the long-term survival of patients with malignant pleural mesothelioma who underwent surgical treatment…
Read MoreTowards a new approach in pleural mesothelioma: Perioperative immunotherapy and its implications
Critical Reviews in Oncology/Hematology 2025 July 23 [Link] Paolo Ambrosini, Alessia Stanzi, Giuseppe Lo Russo, Piergiorgio Solli, Mario Occhipinti Abstract Pleural mesothelioma is a rare malignancy that has historically had a poor prognosis, even with systemic chemotherapy. Although immune checkpoint inhibitors have improved survival rates for patients with advanced, unresectable disease, their role in perioperative…
Read MoreEnhanced efficacy of immune checkpoint inhibitors with OK-432 in malignant pleural mesothelioma: A case report
Molecular and Clinical Oncology 2025 July 3 [Link] Kazuki Yamada, Takehiro Uemura, Aya Mukai, Tatsuya Tanaka, Ippei Sakakibara, Keima Ito, Yuta Mori, Kensuke Fukumitsu, Satoshi Fukuda, Yoshihiro Kanemitsu, Tomoko Tajiri, Yutaka Ito, Tetsuya Oguri, Akio Niimi Abstract Malignant pleural mesothelioma (MPM) is a rare and highly aggressive cancer with limited treatment options and poor prognosis.…
Read MoreNeoadjuvant immunotherapy in a solitary, isolated peritoneal mesothelioma involving the abdominal wall: a case report
Immunotherapy 2025 July [Link] Parsa Charkhchi, Ryan Le, Taryn E Cazzolli, Raina R Flores, Roberto A Martinez, Supreet Kaur, Mio Kitano Abstract Mesothelioma is a rare neoplasm with a minority of cases originating from the peritoneum. Patients are generally treated with a combination of cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, and various systemic therapies. In recent…
Read MoreSerum mesothelin as a response biomarker in pleural mesothelioma
Lung Cancer 2025 August [Link] Geraldine A Lynch, Jenny Symonds, Anna Morley, Emeka Azubuike-Dyer, Will Cooper, Anthony Edey, Duneesha De Fonseka, Selina Tsim Kevin Blyth Paul White, Nick A Maskell 5, Anna Bibby Abstract Background: CT scans are the current gold standard for disease monitoring for Pleural mesothelioma (PM), with radiology reported using the modified…
Read MoreSerum mesothelin as a response biomarker in pleural mesothelioma
Lung Cancer 2025 August [Link] Geraldine A Lynch, Jenny Symonds, Anna Morley, Emeka Azubuike-Dyer, Will Cooper, Anthony Edey, Duneesha De Fonseka, Selina Tsim, Kevin Blyth, Paul White, Nick A Maskell, Anna Bibby Abstract Background: CT scans are the current gold standard for disease monitoring for Pleural mesothelioma (PM), with radiology reported using the modified RECIST…
Read MoremicroRNA-497-5p-based screening identifies a novel synthetic lethal-type interaction via PKMYT1 and WEE1 in pleural mesothelioma
Molecular Therapy, Nucleic Acids 2025 June 17 [Link] Nathanael Pruett, Sierra Wilferd, Anand Singh, Agnes Y Choi, Shivani Dixit, Vivek Singh, Charlize Nguyen, Olivia Lin, David S Schrump, Christopher L Plaisier, Chuong D Hoang Abstract Diffuse pleural mesothelioma (DPM) is an incurable surface neoplasm governed by tumor suppressor losses with limited therapeutic options. Despite the…
Read MoreLong Road to Identifying Peritoneal Mesothelioma: An Elusive Diagnosis
Cureus 2025 June 13 [Link] Thejas Swaroop Konduru, Gourav Gourisaria, Goksu Ozen, Pradeep Karunakaran Thozhuthumparambil Abstract Peritoneal mesothelioma is a rare and aggressive malignancy that often presents with non-specific abdominal symptoms such as ascites, leading to delayed diagnosis and treatment. It poses significant diagnostic challenges, especially in the absence of classical risk factors like asbestos…
Read MoreThe Evolving Role of Chemotherapy in the Management of Pleural Malignancies: Current Evidence and Future Directions
Cancers 2025 June 25 [Link] Yuliya Semenova, Zhandos Burkitbayev, Nurtas Kalibekov, Alexandr Digay, Bakhyt Zhaxybayev, Oxana Shatkovskaya, Saule Khamzina, Dinara Zharlyganova, Zhuldyz Kuanysh, Almira Manatova Abstract Pleural malignancies represent a clinically devastating group of oncological disorders, most commonly arising from metastatic disease, with lung and breast cancers being the most frequent primary sites. Malignant pleural…
Read MoreMedical Thoracoscopy in Malignant Pleural Effusion
Cureus 2025 June 10 [Link] Amit K Rath, Sudarsan Pothal, Pallavi Bharadwaj Abstract Introduction: Malignant pleural effusion (MPE) is a common complication of advanced malignancies, often resulting in significant morbidity and impaired quality of life. In most cases, pleural fluid cytology remains negative. In the era of targeted cancer therapy, pathologists expect larger tissue samples.…
Read More